img

STATUS Current
FUND Life Sciences

Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company, founded in 2012, by Professor Sir Shankar Balasubramanian FRS and Dr. Bobby Yerramilli-Rao. CEGX is seeking to revolutionize genome sequencing through a proprietary technology platform that has the potential to deliver step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.  This is bringing closer the day when advanced medicines, diagnostics and personalized treatments become a reality for all

The Cambridge Epigenetix platform, extends the information content of sequencing by unambiguously identifying five letters of DNA – four genetic bases (A-T-C-G) plus methylated cytosine (5mC or 5hmC).  This information is captured at single base resolution from very small amounts of DNA, and with an accuracy that exceeds other known methods.  This approach can significantly reduce sequencing costs whilst preserving complexity, facilitating rapid and lower cost data analysis.

Epigenetic marks are a vital source of biological information to enable the next generation of diagnostics including those for early cancer detection.  The laboratory component of CEGX’s product is already in manufacture and kits, with associated software, are expected to be available in early 2022.  This will be followed by the launch of additional multiomic products from this platform, the next being a 6-letter kit’ (adding the epigenetic marker hydroxymethylcytosine). CEGX is developing further technology platforms supported by their extensive IP portfolio.

In late 2021, the JIMCO Life Sciences Fund participated in Cambridge Epigenetix’s US$ 88 million Series D funding round.

Series D Extension Nov 2021
FOUNDING TEAM
  • Prof. Sir Shankar Balasubramanian FRS
    Co-Founder and Director
  • Dr. Bobby Yerramilli-Rao
    Co-Founder and Director
FOUNDED
website

Easily integrating into existing sequencers, the company’s products allow the user to see at-a-glance genomic and epigenetic information. Such information can be employed to detect, diagnose, treat and understand disease.  Based in Cambridge, UK, the company is founded by a pioneer in DNA sequencing intent on leading the next great leap forward in genomics.

News from our Portfolio Businesses

The brands and business in the JIMCO investment portfolio are making the news around the world as their transformational approach to global challenges is enabling all of us to take steps towards a more beautiful tomorrow.

You can catch-up with some of their latest headlines here:

img
July 22, 2022
Cambridge Epigenetix

For all of you non-scientists out there, the CDC gives

img
img
July 22, 2022
Cambridge Epigenetix

Epigenome-wide DNA methylation patterns in convalescent...

img
img
July 12, 2022
Cambridge Epigenetix

Exciting news – Lifting the lid on our technology!Paper...

img
img
April 28, 2022
Cambridge Epigenetix

Join Cambridge Epigenetix’ co-founder Professor Shankar...

img
img
April 28, 2022
Cambridge Epigenetix

Announcing the signing of an $88 million Series D finan...

img
img
April 28, 2022
Cambridge Epigenetix

Have you seen the #BIAFinanceReport yet?👀Download the ...

img

Important note: these news items are links to external third-party content and will open in a new tab. These links are provided for your information only. JIMCO has, unless explicitly indicated otherwise, no control over the content of those sites or resources and has no rights in the content of those sites or in the resources. JIMCO assumes no responsibility for the content of websites linked on the JIMCO Website. Such links should not be interpreted as endorsement by JIMCO nor Abdul Latif Jameel of those linked websites therein.

Explore other partners

Lilac Logo
Lilac's ion exchange technology - the fastest, most sustainable, and most efficient lithium extraction platform.